Initiative for Medicines, Access & Knowledge

Four in five Americans support patent reform to lower drug prices, new survey finds A new national survey reveals overwhelming bipartisan support for overhauling the patent system to address soaring prescription drug costs in the United

“Patent reform is our best path forward for addressing a root cause of high drug prices in a bipartisan manner.” @tahiramin.bsky.social
www.statnews.com/sponsor/2025...

This is true. Look at AbbVie’s CEO. It says a lot about a pharma company's priorities when their CEO's bio focuses entirely on financial achievements.

SENATOR WELCH: Pharmaceutical companies used to be run by scientists. They’re now run by MBAs.

How a Drug Company Made $114 Billion by Gaming the U.S. Patent System (Published 2023)

As @tahiramin.bsky.social said, AbbVie leveraged its massive patent thicket to extend its market monopoly on Humira by 7 years. During that period, the company raised the price over 60%, generating $114 billion in revenue.
www.nytimes.com/2023/01/28/b...

During our recent webinar, @tahiramin.bsky.social, @welch.senate.gov, and @emilypisacreta.bsky.social looked back at a 2019 exchange between Sen. John Cornyn and former AbbVie CEO Richard Gonzalez, in which Gonzalez openly admitted to stockpiling hundreds of patents on Humira.

Four in five Americans support patent reform to lower drug prices, new survey finds A new national survey reveals overwhelming bipartisan support for overhauling the patent system to address soaring prescription drug costs in the United

NEW: We partnered with @statnews.com to analyze findings from a national @fandmpoll.bsky.social survey we commissioned to understand the public’s top concerns on drug pricing.
www.statnews.com/sponsor/2025...

Jon Stewart and Lina Khan discuss how pharma companies build patent thickets.

NEWS: @tahiramin.bsky.social sat down with Nick Robertson of MLex to discuss how we’re helping Congress and the public understand the connection between patent abuse and high drug prices.

Read the interview: www.mlex.com/mlex/article...

Understanding Americans’ Top Concerns on Drug Pricing: Corporate Greed and Patent Reform I-MAK commissioned a survey of 726 American adults to assess public attitudes toward prescription drug pricing and potential reforms. Conducted by Franklin & Marshall College’s Center for Opinion Rese...

The survey of 726 Americans reveals strong bipartisan support for healthcare reform measures, particularly patent system changes that could increase market competition and reduce drug prices.
reports.i-mak.org/drug-pricing...

New survey shows Americans want patent reform Building a more just and equitable medicines system for all

In our November newsletter, @tahiramin.bsky.social discusses findings from a new nationwide survey we commissioned from the Center for Opinion Research at Franklin and Marshall College.
www.i-mak.org/2025/11/10/n...

Sen. @hassan.senate.gov (D-NH): What are the real impacts of these patent games on patients?

Dr. @wbfeldman.bsky.social: These patent games can delay generic and biosimilar competition, which keep prices high...patients can’t afford their medications and we see worse clinical outcomes.

Senator Susan Collins (R-ME) took time during a recent hearing on 340B reform to highlight the importance of patent reform.

Watch the full exchange here👇

Last week, the Senate HELP Committee held a hearing on 340B reform. During the hearing, Sen. Hawley (R-MO) asked @wbfeldman.bsky.social how we can lower drug prices for Americans. Dr. Feldman outlined several steps we can take while making clear that patent reform is critical.

TrumpRx and a most favored nation policy won’t lower prices for patients TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.

TrumpRx and a most-favored nation policy won’t lower drug prices for patients. We need a government that is willing to stand up to corporate interests and actually become a most favored nation for patients, not pharmaceutical profits.

New op-ed for @statnews.com ↓
www.statnews.com/2025/10/24/t...

TrumpRx and a most favored nation policy won’t lower prices for patients TrumpRx and a most-favored nation policy won’t lower prices for patients, writes the CEO and co-founder of I-MAK.

Thank to our colleagues of @imakglobal.bsky.social
for this strong analyse : www.statnews.com/2025/10/24/t...

Swipe to see how readers are reacting 👇

As Rebecca Robbins of the Times details, Amgen—the company that markets Enbrel—has relied on legal loopholes and anti-competitive patenting schemes to extend its monopoly over the drug and block American patients from accessing cheaper biosimilar versions.

Enbrel is a biologic drug used to treat several conditions, including rheumatoid arthritis and plaque psoriasis. The list price was about $11,000 for an annual treatment when it first launched nearly 30 years ago. Today, it’s $106,000 and it has no competition.

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

🚨NEW: @nytimes.com reports on Colorado’s effort to curb the price of Enbrel.

“The fact the government never stepped in to rectify this extended patent monopoly is a case to be studied.” - @tahiramin.bsky.social

www.nytimes.com/2025/10/23/h...

🗞️ @statnews.com highlights key findings from a new national survey we commissioned to understand Americans’ top concerns on drug pricing.

🔗 www.statnews.com/pharmalot/20...

⏰ Our webinar is starting in 1 hour!

Tune in to learn about results from a new national survey showing strong bipartisan support for patent reform.

Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social

Understanding Americans’ Top Concerns on Drug Pricing: Corporate Greed and Patent Reform Building a more just and equitable medicines system for all

Also, don’t forget to RSVP to our webinar tomorrow morning, where we’ll review new survey results that break down the growing bipartisan support for patent system reform! We’ll hear from @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, and @emilypisacreta.bsky.social.
www.i-mak.org/survey/

Keytruda Qlex: Where’s the invention? Building a more just and equitable medicines system for all

In our October newsletter, @tahiramin.bsky.social asks a simple but critical questions about Merck's Keytruda Qlex: does it really count as an invention?
www.i-mak.org/2025/10/17/k...

4 in 5 Americans support changes to patent laws to address drug pricing

Join us tomorrow at 10AM ET for a webinar unpacking results from a new national survey showing strong bipartisan support for patent reform.

RSVP here: www.i-mak.org/survey/

Did you RSVP to our webinar?

A new national survey reveals bipartisan support for patent system reforms

🗓️ Wednesday, October 22
🕙 10AM ET
🗣️ @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social
🎟️ www.i-mak.org/survey/

Looking forward to this conversation about drug prices next week!

JOIN US! On Wednesday, October 22 at 10AM ET we will host a webinar to discuss results from a new national survey revealing bipartisan momentum for patent system reform.

Speakers: @tahiramin.bsky.social, @welch.senate.gov, Berwood Yost, @emilypisacreta.bsky.social

RSVP! www.i-mak.org/survey/

Swipe to see how readers are reacting 👇

States fed up with high drug prices are cracking down A Colorado panel voted Friday to cap the price for a best-selling drug from Amgen. It is one of four states that have passed legislation allowing price caps for specific prescriptions.

🚨 @washingtonpost.com reports on Colorado’s effort to lower the price of Enbrel—the latest state-level move to curb patent abuse in order to make life-saving drugs affordable for the patients that need them. The article features data from our team at I-MAK.
www.washingtonpost.com/health/2025/...